AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32674209 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 32674336 — intervention group
Group type: EXPERIMENTAL
Intervention: Convection Enhanced Delivery (CED)
Number of subjects: 0
Study 32674461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib + Pravastatin
Number of subjects: 31
Study 32674461 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 31
Study 32674634 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab, 480 mg every 4 weeks for 6 weeks
Number of subjects: 30
Study 32675047 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Scintigraphy (BS)
Number of subjects: 80
Study 32675047 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 80
Study 32675047 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced imaging modalities
Number of subjects: 80
Study 32675047 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging modalities
Number of subjects: 80
Study 32675217 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Hypertension (PH)
Number of subjects: 200
Study 32675217 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular Dysfunction (RVD)
Number of subjects: 200
Study 32675274 — intervention group
Group type: EXPERIMENTAL
Intervention: Practices without central QI support
Number of subjects: 205
Study 32675274 — intervention group
Group type: COMPARATOR
Intervention: Practices with central QI support
Number of subjects: 205
Study 32675292 — intervention group
Group type: COMPARATOR
Intervention: Evening chronotypes (reference group)
Number of subjects: 635
Study 32675292 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotype preference (morning, intermediate, evening)
Number of subjects: 635
Study 32676125 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing on provider-collected specimens
Number of subjects: 566
Study 32676125 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing on self-collected specimens
Number of subjects: 566
Study 32676125 — intervention group
Group type: COMPARATOR
Intervention: Visual Inspection after Acetic Acid (VIA)
Number of subjects: 566
Study 32676125 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall high-grade cervical abnormality detection
Number of subjects: 566
Study 32676205 — intervention group
Group type: EXPERIMENTAL
Intervention: iStent implantation in patients with baseline IOP < 26 mmHg
Number of subjects: 72
Study 32676205 — intervention group
Group type: EXPERIMENTAL
Intervention: iStent implantation in patients with baseline IOP ≥ 26 mmHg
Number of subjects: 72
Study 32676681 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency medical service (EMS) transported patients
Number of subjects: 15800
Study 32676681 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing logistic structure in regional STEMI networks
Number of subjects: 15800
Study 32676681 — intervention group
Group type: COMPARATOR
Intervention: Total number of STEMI patients treated
Number of subjects: 15800
Study 32676697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmologist's medical report
Number of subjects: 810
Study 32676697 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated documents
Number of subjects: 810
Study 32676697 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwritten documents
Number of subjects: 810
Study 32676697 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard form of national guidelines
Number of subjects: 810
Study 32676697 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-designed formats
Number of subjects: 810
Study 32676697 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed letters
Number of subjects: 810
Study 32676697 — intervention group
Group type: EXPERIMENTAL
Intervention: Short reports
Number of subjects: 810
Study 32676697 — intervention group
Group type: EXPERIMENTAL
Intervention: Short messages
Number of subjects: 810
Study 32676697 — intervention group
Group type: EXPERIMENTAL
Intervention: Report rate
Number of subjects: 810
Study 32676697 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of reports
Number of subjects: 810
Study 32676697 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of DR in forms
Number of subjects: 810
Study 32676702 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic low-lipid tasters
Number of subjects: 2
Study 32676702 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic high-lipid tasters
Number of subjects: 2
Study 32676702 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 2
Study 32676702 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated with metformin and/or statins
Number of subjects: 2
Study 32676727 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic sphincter augmentation (MSA)
Number of subjects: 631
Study 32676727 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic fundoplication (LF)
Number of subjects: 631
Study 32676980 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL) measured by WHOQOL-BREF
Number of subjects: 27
Study 32676980 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported impairments measured by SIPP-RS
Number of subjects: 27
Study 32676980 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of daily living measured by IBM-FRS
Number of subjects: 27
Study 32676980 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walking distance (6MWD)
Number of subjects: 27
Study 32676980 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor function measure (MFM)
Number of subjects: 27
Study 32676980 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of daily living
Number of subjects: 27
Study 32677025 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive PCR test
Number of subjects: 17787
Study 32677025 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive serological test
Number of subjects: 17787
Study 32677025 — intervention group
Group type: EXPERIMENTAL
Intervention: Population estimate of SARS-CoV-2 infection
Number of subjects: 17787
Study 32677025 — intervention group
Group type: EXPERIMENTAL
Intervention: Population estimate of seropositivity
Number of subjects: 17787
Study 32677025 — intervention group
Group type: EXPERIMENTAL
Intervention: Active infection rate
Number of subjects: 17787
Study 32677025 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of prior SARS-CoV-2 exposure
Number of subjects: 17787
Study 32677025 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported symptoms (loss of smell or taste, body aches)
Number of subjects: 17787
Study 32677106 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-Epicatechin (EPI) at 75 mg/d for 24 weeks, escalating to 150 mg/d at 12 weeks if no improvement
Number of subjects: 10
Study 32677106 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-Epicatechin (EPI)
Number of subjects: 10
Study 32677243 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR plus usual care (8 sessions of 2 hr/week)
Number of subjects: 85
Study 32677243 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 85
Study 32677467 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32677894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving personalized care practices developed using the Balance of Care methodology, including training for healthcare professionals.
Number of subjects: 430
Study 32677894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 430
Study 32677968 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis-B vaccine with five different adjuvant formulations
Number of subjects: 0
Study 32677985 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 200
Study 32677985 — intervention group
Group type: COMPARATOR
Intervention: Control (without levosimendan)
Number of subjects: 200
Study 32677997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptin in synovial fluid
Number of subjects: 20
Study 32677997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptin in plasma pre-procedure
Number of subjects: 20
Study 32677997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptin in plasma post-tourniquet deflation
Number of subjects: 20
Study 32677997 — intervention group
Group type: COMPARATOR
Intervention: Comparison of nociceptin concentration in synovial fluid vs plasma pre-procedure
Number of subjects: 20
Study 32677997 — intervention group
Group type: COMPARATOR
Intervention: Comparison of nociceptin concentration in synovial fluid vs plasma post-tourniquet deflation
Number of subjects: 20
Study 32677997 — intervention group
Group type: COMPARATOR
Intervention: Comparison of nociceptin concentration in females vs males
Number of subjects: 20
Study 32678292 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32678426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal hypertension (IAH)
Number of subjects: 107
Study 32678426 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index >25 kg/m2
Number of subjects: 107
Study 32678426 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous history of peritoneal dialysis
Number of subjects: 107
Study 32678426 — intervention group
Group type: EXPERIMENTAL
Intervention: IAH Grades III and IV
Number of subjects: 107
Study 32678426 — intervention group
Group type: EXPERIMENTAL
Intervention: IAH patients
Number of subjects: 107
Study 32678426 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolution of intravesical pressure (IVP)
Number of subjects: 107
Study 32678436 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week blueberry-enriched diet (38 g of freeze-dried blueberries daily)
Number of subjects: 22
Study 32678436 — intervention group
Group type: EXPERIMENTAL
Intervention: acute blueberry-enriched diet serum
Number of subjects: 22
Study 32678436 — intervention group
Group type: COMPARATOR
Intervention: 6-week blueberry-enriched diet serum
Number of subjects: 22
Study 32680417 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy for groups (IPTG)
Number of subjects: 489
Study 32680417 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 489
Study 32680448 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime Engagement Scale (18-item scale)
Number of subjects: 87
Study 32680448 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing one-on-one assistance
Number of subjects: 87
Study 32680448 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-approaching individual to continue meal
Number of subjects: 87
Study 32680448 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasch model
Number of subjects: 87
Study 32680448 — intervention group
Group type: EXPERIMENTAL
Intervention: Item Response Theory models
Number of subjects: 87
Study 32680480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg once daily for 12 weeks, followed by 12-week dose titration (up to 10 mg)
Number of subjects: 71
Study 32680541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraovarian injection of autologous bone marrow-derived mesenchymal stem cells
Number of subjects: 2
Study 32680942 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI
Number of subjects: 64
Study 32680942 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic manifestations
Number of subjects: 64
Study 32681140 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anterior resection for rectal cancer
Number of subjects: 125
Study 32681140 — intervention group
Group type: COMPARATOR
Intervention: Preoperative (chemo)radiotherapy
Number of subjects: 125
Study 32681472 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB-FHbp vaccine (120 µg at 0, 2, 6 months)
Number of subjects: 8026
Study 32681477 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy (ECT) with Irreversible Electroporation (IRE) and FOLFIRINOX
Number of subjects: 5
Study 32681477 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy (ECT) with IRE and FOLFIRINOX
Number of subjects: 5
Study 32681477 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy (ECT) with either FOLFIRINOX or gemcitabine
Number of subjects: 5
Study 32681477 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRINOX alone
Number of subjects: 5
Study 32681477 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 5
Study 32681477 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine + IRE
Number of subjects: 5
Study 32681477 — intervention group
Group type: COMPARATOR
Intervention: IRE alone
Number of subjects: 5
Study 32681659 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Number of subjects: 33
Study 32681659 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of C3c
Number of subjects: 33
Study 32681659 — intervention group
Group type: EXPERIMENTAL
Intervention: C3c levels
Number of subjects: 33
Study 32681659 — intervention group
Group type: COMPARATOR
Intervention: C3 and C3c levels
Number of subjects: 33
Study 32681659 — intervention group
Group type: COMPARATOR
Intervention: C3 levels
Number of subjects: 33
Study 32681682 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 39
Study 32681682 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily (EXP3B subgroup)
Number of subjects: 39
Study 32681700 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 levels
Number of subjects: 96
Study 32681700 — intervention group
Group type: EXPERIMENTAL
Intervention: CST levels
Number of subjects: 96
Study 32681700 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 as a predictor of in-hospital death
Number of subjects: 96
Study 32681700 — intervention group
Group type: EXPERIMENTAL
Intervention: CST as a predictor of in-hospital death
Number of subjects: 96
Study 32681700 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 AUC for classifying non-survivors from survivors
Number of subjects: 96
Study 32681700 — intervention group
Group type: EXPERIMENTAL
Intervention: CST AUC for classifying non-survivors from survivors
Number of subjects: 96
Study 32681700 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP AUC for classifying non-survivors from survivors
Number of subjects: 96
Study 32681700 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 levels ≥35 ng/mL among survivors
Number of subjects: 96
Study 32681700 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of sST2 and CST levels
Number of subjects: 96
Study 32682441 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional, structural, and patient-reported candidate outcomes in the cross-sectional part (1 month duration)
Number of subjects: 0
Study 32682441 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional, structural, and patient-reported outcomes in the longitudinal part (36 months duration)
Number of subjects: 0
Study 32682451 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index group I (lowest)
Number of subjects: 1143
Study 32682451 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index group II
Number of subjects: 1143
Study 32682451 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index group III (highest)
Number of subjects: 1143
Study 32682555 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with isoflurane
Number of subjects: 1002
Study 32682670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren (a read-through agent for premature nonsense codons)
Number of subjects: 751
Study 32682670 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuchs criteria definitions
Number of subjects: 751
Study 32682670 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuchs criteria assessment
Number of subjects: 751
Study 32682713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (1.5-T)
Number of subjects: 134
Study 32682715 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced PALS (PALS ≤18%)
Number of subjects: 2461
Study 32682715 — intervention group
Group type: COMPARATOR
Intervention: Normal PALS (PALS >18%)
Number of subjects: 2461
Study 32682718 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-FT global longitudinal peak strain (GLS)
Number of subjects: 455
Study 32682718 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-FT
Number of subjects: 455
Study 32682714 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe stress B-lines (score ≥10)
Number of subjects: 2145
Study 32682714 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal heart rate reserve
Number of subjects: 2145
Study 32682714 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal coronary flow velocity reserve
Number of subjects: 2145
Study 32682714 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2145
Study 32682875 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep medications (including benzodiazepines)
Number of subjects: 0
Study 32683101 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of LAMS with plastic stents after removal of LAMS
Number of subjects: 94
Study 32683101 — intervention group
Group type: COMPARATOR
Intervention: No replacement of LAMS with plastic stents
Number of subjects: 94
Study 32683101 — intervention group
Group type: COMPARATOR
Intervention: Patients with intact pancreatic ducts
Number of subjects: 94
Study 32683101 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recurrence in patients with DPDS
Number of subjects: 94
Study 32683126 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflac-AML regimen (anthracycline-reduced approach)
Number of subjects: 27
Study 32683127 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation (allo-HSCT) with post-transplant cyclophosphamide (PTCy)
Number of subjects: 0
Study 32683528 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgravity exposure (μg)
Number of subjects: 15
Study 32683528 — intervention group
Group type: COMPARATOR
Intervention: Control (1g)
Number of subjects: 15
Study 32683644 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tramadol 50 mg
Number of subjects: 0
Study 32683644 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tramadol 25 mg
Number of subjects: 0
Study 32683644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32683763 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder
Number of subjects: 113
Study 32684069 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Training
Number of subjects: 0
Study 32684069 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32684363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy products (FDP) consumption
Number of subjects: 1185
Study 32684363 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating short-chain acylcarnitines (SCA)
Number of subjects: 1185
Study 32684363 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcarnitine (C2)
Number of subjects: 1185
Study 32684363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk consumption
Number of subjects: 1185
Study 32684363 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-chain acylcarnitines (SCA) and acetylcarnitine (C2)
Number of subjects: 1185
Study 32685131 — intervention group
Group type: EXPERIMENTAL
Intervention: Polynerve synthetic polymer nerve conduit
Number of subjects: 0
Study 32685552 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission hyperglycemia
Number of subjects: 277
Study 32685552 — intervention group
Group type: EXPERIMENTAL
Intervention: A/C (arterial blood glucose)
Number of subjects: 277
Study 32685766 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention for managing risk factors in diabetic kidney disease (STOP-DKD)
Number of subjects: 0
Study 32685766 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention for cardiovascular improvement (CITIES)
Number of subjects: 0
Study 32685766 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 0
Study 32686047 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 2719
Study 32686047 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2719
Study 32686047 — intervention group
Group type: COMPARATOR
Intervention: High-volume centre
Number of subjects: 2719
Study 32687189 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva Iodine Concentration (SIC) <105 μg/L
Number of subjects: 0
Study 32687189 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva Iodine Concentration (SIC) >273 μg/L
Number of subjects: 0
Study 32687189 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva Iodine Concentration (SIC)
Number of subjects: 0
Study 32687189 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva Iodine Concentration (SIC) quantiles
Number of subjects: 0
Study 32687473 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost electronic adherence monitoring combined with data-informed counseling, SMS-based support, and/or alarms
Number of subjects: 49
Study 32687478 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based integrative family intervention (WIFI) including psychoeducation, peer support, and professional support.
Number of subjects: 12
Study 32687478 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based integrative family intervention (WIFI)
Number of subjects: 12
Study 32687478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost data collection
Number of subjects: 12
Study 32687478 — intervention group
Group type: EXPERIMENTAL
Intervention: Process data collection
Number of subjects: 12
Study 32687629 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmacological interventions (dietary, exercise, behavioural, multi-component)
Number of subjects: 0
Study 32687629 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological interventions (weight loss medications, medication switching)
Number of subjects: 0
Study 32687629 — intervention group
Group type: COMPARATOR
Intervention: Surgical interventions (gastric bypass, gastric bands, biliopancreatic diversion, vertical banded gastroplasty)
Number of subjects: 0
Study 32687899 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA) over left PFC
Number of subjects: 9
Study 32687899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (1 mA) over left PFC
Number of subjects: 9